PMLiVE5d
AstraZeneca’s Fasenra approved by EC to treat rare inflammatory disease EGPA
AstraZeneca’s Fasenra (benralizumab) has been approved by the European Commission (EC) to treat eosinophilic granulomatosis ...
pulmonologyadvisor8d
Switching Biologics Occurs in 16% of Patients With Asthma, for Various Reasons
Patients with asthma who switched biologics multiple times were younger, more likely to identify as Black, and had more ...
biopharma-reporter12d
AstraZeneca’s rare disease therapy Fasenra receives EU approval
The new treatment will be a competitor of GSK’s Nucala (mepolizumab), which was approved in 2018 as the first targeted ...
EC approves AstraZeneca’s Fasenra for EGPA treatment
The European Commission (EC) has approved AstraZeneca's Fasenra (benralizumab) as an add-on therapy for adults with relapsing ...
Pharmabiz12d
European Union approves AstraZeneca’s Fasenra for eosinophilic granulomatosis with polyangiitis
AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis ...
EuropaWire12d
AstraZeneca’s Fasenra Approved in EU for Treating Rare Vasculitis, Offering New Hope for EGPA Patients
AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union as an add-on treatment for adults with eosinophilic granulomatosis ...
PharmiWeb13d
Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis
New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroidsAstraZeneca’s Fasenra (benralizumab) ...
Frontiers17d
Updated insights into adverse events associated with mepolizumab: a disproportionality analysis from the FDA adverse event reporting system database
This study aimed to investigate the safety of mepolizumab by analyzing the pharmacovigilance database of the US Food and Drug Administration. Methods: The AE signals associated with mepolizumab from ...
EuropaWire27d
GSK Reports Promising Phase III Findings for Depemokimab in Treating Chronic Rhinosinusitis with Nasal Polyps
(IN BRIEF) GSK plc has announced positive results from its Phase III ANCHOR trials for depemokimab, a biologic treatment for chronic rhinosinusitis with nasal polyps (CRSwNP). The trials demonstrated ...